Last reviewed · How we verify
High dose potent statin
High-dose potent statins inhibit HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels in the blood.
High-dose potent statins inhibit HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels in the blood. Used for Hypercholesterolemia and dyslipidemia, Primary and secondary prevention of cardiovascular disease.
At a glance
| Generic name | High dose potent statin |
|---|---|
| Also known as | atorvastatin or rosuvastatin |
| Sponsor | University of Florida |
| Drug class | HMG-CoA reductase inhibitor (statin) |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Statins competitively inhibit the enzyme HMG-CoA reductase, which catalyzes an early rate-limiting step in cholesterol biosynthesis. By reducing hepatic cholesterol production, statins trigger upregulation of LDL receptors on liver cells, increasing clearance of LDL cholesterol from circulation. High-dose formulations achieve greater LDL reduction and are used in patients requiring intensive lipid lowering.
Approved indications
- Hypercholesterolemia and dyslipidemia
- Primary and secondary prevention of cardiovascular disease
Common side effects
- Muscle pain or myalgia
- Elevated liver enzymes
- Headache
- Rhabdomyolysis (rare)
Key clinical trials
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (PHASE4)
- LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High dose potent statin CI brief — competitive landscape report
- High dose potent statin updates RSS · CI watch RSS
- University of Florida portfolio CI